WELCOME TO The Biotechnology REPORT
Newsletter | Member Login | Signup
Home > Companies > Central Health
Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...
Cell and Gene Therapy
Tevogen Bio | January 13, 2022
Tevogen Bio, a clinical stage biotechnology company specializing in cell and gene therapies in oncology and viral infections, announced that the U.S. Patent and Trademark Office has granted a new patent for the method of preparing COVID-19 peptide specific cytotoxic T cells for the treatment of COVID-19 infection. The patent further reinforces the biotech pioneer’s expanding IP portfolio. “Omicron’s extensive mutations and its subsequent abi...
Medical
Frontage | January 02, 2024
Frontage Laboratories, Inc. announced that, through its wholly-owned subsidiary Frontage Europe S.r.l., it has completed the acquisition of the Bioanalytical and Drug Metabolism & Pharmacokinetics businesses of Accelera S.r.l (Accelera). Accelera is a premier Contract Research Organization located in Nerviano, within the Lombardy region of Italy, part of the well-established NMS Group S.p.A. which has positioned itself as a global niche player in delivering discovery &...
Phytolon; Ginkgo Bioworks | February 28, 2022
Phytolon, a growing startup company making natural food colorants, announced a partnership today with Ginkgo Bioworks the leading horizontal platform for cell programming, to produce vibrant cultured food colors via fermentation of yeast. Under this partnership, Phytolon is leveraging Ginkgo's ability to engineer biology at scale to work together on the production of vibrant betalain pigments, the healthy and colorful compounds found in foods like beets and cactus fruit. The project aims to ...
ElevateBio | November 25, 2021
ElevateBio, LLC, a cell and gene therapy technology company focused on powering transformative cell and gene therapies, announced that the United States Patent and Trademark Office has issued US Patent No. 11,162,114 with an anticipated expiry date of June 23, 2040, inclusive of 384 days of patent term adjustment . This patent, issued to LifeEDIT Therapeutics, Inc. is the first to provide composition and methods of use protection for various RNA-guided nucleases in Life Edit’s gene editing...
Article
Keep me plugged in with the best
Join thousands of your peers and receive our weekly newsletter with the latest news, industry events, customer insights, and market intelligence.
Welcome back!
Put your news, events, company, and promotional content in front of thousands of your peers and potential customers.
Not a member yet? Not a problem, Sign Up
Sign up
Sign up to contribute and publish your news, events, brand, and content with the community for FREE